Your SlideShare is downloading. ×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015

951

Published on

Published in: Business
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
951
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
18
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Get more info on this report!Whats Next in Biologics? (mAbs, rDNA, Interferons, and OtherBiologics) 2011-2015May 1, 2011The future of the pharmaceutical market will be determined by biologics - drugsproduced by natural organisms or recombinant techniques consisting of proteins andother products derived from living organisms for the treatment or management ofdiseases or injuries. What are the products that lead the market now and what can weexpect to see in the coming years?Find out in Kalorama Informations report, Whats Next in Biologics?, which representsour latest research into the market for non-vaccine biological drugs and the companieswho compete in the market.The following are among the data points in this report: Biopharmaceutical Pipeline for Significant Companies Market Size of Biopharmaceuticals o Monoclonal Antibodies (mAbs) o Recombinant Hormones and Proteins (rDNA) o Interferons and o Other Biologics Biopharmaceutical Market Forecast to 2015 Products in Development: New Compound vs. Additional Indications Competitor Market Shares for Biopharmaceuticals Autoimmune, Cancer, Cardiovascular and Hormone Treatments Market Sizes and Competitor Shares Drug Development Cost Progression Leading Biotech Therapies by 2010 Revenues Population and Healthcare Spending Trends Select Biotechnology Drugs Approved for MarketingThe biologics industry encompasses a wide range of products including monoclonalantibodies, blood products, vaccines, and some diagnostics and devices. For thepurpose of this study, Kalorama Information focuses on those biologics that are used inconjunction with, or as a replacement to, traditional pharmaceutical treatments. Forexample, treatments for cancer, growth disorders, autoimmune diseases and blooddisorders. This study excludes products such as vaccines—including prophylactic
  • 2. vaccines—which are covered in-depth in separate Kalorama studies.The following topics are among the qualitative analysis found in this report: The Role Government Incentives Will Play in the Future Biotech Market Pharmaceutical Regulatory Exclusivity Biosimilars: Where They Stand and What We Can Expect The Largest Areas of Research for Biopharmaceuticals Improvements in the Next Generation of Biologics The Impact of Aging Populations on Biotechnology Market Development Health Care Reform: What it Means Recent Mergers, Acquisitions, and Collaborations Contributors to R&D Success Targeted Cancer Therapy Genome Sequencing for Personalized Healthcare The Role of Contract Research OrganizationsIn the traditional pharmaceutical market, the pipeline is struggling to produce strongtherapies and the growing number of drugs losing patent protection will more than offsetrevenues generated from new developments. For now, the biotechnology market isspared the impact of this setback as the path to generic or biosimilar development ismore involved and the number of biotechnology drugs facing generic competitionremains limited. Many companies are capitalizing on this trend, and among thosediscussed in the report include the following: Abbott Laboratories Amgen Biogen Idec Johnson & Johnson Merck & Co. Merck Serono Novo Nordisk Pfizer Roche/Genentech Sanofi-Aventis/GenzymeAdditional InformationA full biologics pipeline will lead to continued growth in the biopharmaceutical market,according to Kalorama Information. The healthcare market research firm expects annualgrowth of 7.1% through 2015, given the nearly 200 products in late-stage development.According to their latest report, Whats Next in Biologics (mAbs, rDNA, Interferons, and
  • 3. Other Biologics) 2011-2015, the top five biopharmaceutical companies continue todominate this market landscape.A majority of the 200 biologics currently in the development pipeline are aimed at thetreatment of cancers, followed by cardiovascular diseases and autoimmune andhormone disorders. According to the report, monoclonal antibodies account for thelargest share of the innovation with nearly thirty new antibody compounds indevelopment. Multiple companies expecting to profit from the products currently in late-stage development, each of which can cost $1-2 billion to develop, are driving themarkets growth through 2015, when Kalorama expects it to reach just under $150billion."The Phase III pipelines are heavy in this area and that will keep growth up," said BruceCarlson, publisher of Kalorama Information. "The beneficiaries will be a number ofcompanies, though especially the top five. Although a number of smaller companies areoperating in this market, difficulties remain in overcoming the high cost of development."The report details several companies, but indicates that the biologics market is stilldominated by the top five pharmaceutical companies--Amgen, GlaxoSmithKline,Novartis, Pfizer and Roche--which combined hold over a quarter of the late-stageproducts."The big players have a steady flow of new products and extensions coming through thepipeline, with over 100 projects in development," added Carlson. "The strongest pipelineis still held by Roches Genetech."Kalorama Informations Whats Next in Biologics (mAbs, rDNA, Interferons, and OtherBiologics) 2011-2015 looks at the market for non-vaccine biological drugs and thecompanies that compete in the market. The report discusses the biopharmaceuticalpipeline for major companies and provides market size estimates and forecasts formonoclonal antibodies, recombinant hormones and proteins, interferons and otherbiologics.More Drug Discovery Reports by Kalorama InformationLaboratory Information Systems (LIS / LIMS) Markets by Kalorama InformationAutomating instruments in the laboratory has created a demand for similar automationof information management systems, a need for speeding the turnaround of data and ...Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 4thEdition by Kalorama InformationKalorama Informations Outsourcing in Drug Discovery offers unparalleled discussion ofthe drug discovery outsourcing market. It presents viewpoints from both customers andsuppliers. ...The Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) by
  • 4. Kalorama InformationThe anti-infective market is at a critical juncture. For the past 60 years, antibiotic drugshave turned bacterial infections into treatable conditions rather than ...World Veterinary Health Products (Animal Pharmaceuticals, Vaccines, OTC andPerformance Enhancers) by Kalorama InformationThe multi-billion veterinary health products market, though smaller in opportunity ascompared with the human health sector, offers significant return on investment,primarily driven by ...Clinical Nutrition Products: World Markets, 3rd Edition by Kalorama InformationThis Kalorama Information report - Clinical Nutrition - focuses on three primarysegments of essential medical nutrition: Infant Nutrition: (Milk-based, Soy-based,Special Needs such as ...TABLE OF CONTENTSCHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Biopharmaceutical Market Overview Issues and Trends Affecting Market Leading CompaniesCHAPTER TWO: INTRODUCTION Overview of Biopharmaceutical General Biotech Terms Expanded Options in Treating Diseases Disease Descriptions o Autoimmune Diseases o Cardiovascular and Blood Disorders o Cancer o Hormone Disorders o Infectious Diseases o Neurological Disorders Research & Development OverviewCHAPTER THREE: BIOLOGIC PRODUCTS ON THE MARKET Product Segments o Monoclonal Antibodies o Recombinant Hormones and Proteins
  • 5. o Gene Therapy o Interferons/Interleukins o Cell Therapy o Antisense Therapy o Growth Factors Current ProductsCHAPTER FOUR: BIOPHARMACEUTICAL PIPELINES Overview Biopharmaceutical Development Outlook Company R&D Profiles o Abbott o Amgen o Biogen Idec o Bristol-Myers Squibb o Eli Lilly o GlaxoSmithKline o Merck KGaA o Novartis o Novo Nordisk o Pfizer o RocheCHAPTER FIVE: ISSUES AND TRENDS Overview of the Industry The Next Generation of Biologics o Technology for Drug Adherence, Targeted Delivery and Monitoring Government Incentives for Biologic Development Biopharmaceutical and Biosimilar Drug Development Clinical Trial Costs Orphan Drugs Pharmaceutical Regulatory Exclusivity o Pediatric Extensions o Biopharmaceutical Industry—Biosimilar (Biogeneric) Development and Exclusivity Aging Population Healthcare Expenditures Growth o Health Care Reforms Impact on Biopharmaceutical Companies Mergers, Acquisitions, and Collaborations Contributors To R&D Success R&D Spending Cancer Drugs in Development 2011 The Impact of Targeted Therapy in Oncology Genome Sequencing for Personalized Healthcare
  • 6. The Role of Contract Research Organizations Global ExpansionCHAPTER SIX: MARKET SUMMARY Market Overview Biopharmaceutical Product Analysis Market Forecast Geographical Analysis Competitor Analysis o Company Analysis by Therapeutic SegmentCHAPTER SEVEN: COMPANY PROFILES Introduction Abbott Laboratories, Inc Amgen, Inc. Biogen Idec Johnson & Johnson Merck & Co., Inc. Merck Serono Novo Nordisk Pfizer Roche/Genentech Sanofi-Aventis/GenzymeTABLE OF EXHIBITSCHAPTER ONE: EXECUTIVE SUMMARY Table 1-1 Global Biopharmaceutical Treatments (non-vaccine)Market, 2008-2015 Compound Annual Growth Rate Figure 1-1 Global Biopharmaceutical Treatments (non-vaccine)Market, 2008- 2015CHAPTER TWO: INTRODUCTION Table 2-1 World Cancer Incidence by Selected Types of Cancer, 2010 and 2020, all races, both sexes Table 2-2 Total Cancer Incidence by Sex and Country, 2010 Estimates Table 2-3 Phases of Clinical Drug Development in the United StatesCHAPTER THREE: PRODUCT OVERVIEW Table 3-1 Monoclonal Antibody Source Identifiers Figure 3-1 Biopharmaceutical Approvals by Year Range (FDA)
  • 7. Table 3-2 Select Biopharmaceutical Drugs Approved for Marketing Table 3-2 (continued) Select Biopharmaceutical Drugs Approved for Marketing Table 3-2 (continued) Select Biopharmaceutical Drugs Approved for Marketing Table 3-2 (continued) Select Biopharmaceutical Drugs Approved for Marketing Table 3-2 (continued) Select Biopharmaceutical Drugs Approved for MarketingCHAPTER FOUR: DEVELOPMENTS Figure 4-1 Biopharmaceutical Development by General Indication and Development Activity (Phase III through Registration) Table 4-1 New Developments in Biopharmaceutical, Phase III and Beyond Table 4-1 (continued) New Developments in Biopharmaceutical, Phase III and Beyond Table 4-1 (continued) New Developments in Biopharmaceutical, Phase III and Beyond Table 4-1 (continued) New Developments in Biopharmaceutical, Phase III and Beyond Table 4-1 (continued) New Developments in Biopharmaceutical, Phase III and Beyond Table 4-1 (continued) New Developments in Biopharmaceutical, Phase III and Beyond Table 4-1 (continued) New Developments in Biopharmaceutical, Phase III and Beyond Table 4-1 (continued) New Developments in Biopharmaceutical, Phase III and Beyond Figure 4-2 Pipeline Snapshot: Biopharmaceutical Pipelines for New Compounds and Product Extensions by Type Figure 4-3 Select Company Biopharmaceutical Pipelines by Development Status Table 4-2 Abbott’s Biopharmaceutical Pipeline Table 4-3 Amgen’s Biopharmaceutical Pipeline Table 4-3 (continued) Amgen’s Biopharmaceutical Pipeline Table 4-4 Biogen Idec’s Biopharmaceutical Pipeline Table 4-5 Bristol-Myers Squibb’s Late Stage Biopharmaceutical Pipeline Table 4-6 Eli Lilly’s Biopharmaceutical Pipeline Table 4-7 GlaxoSmithKline’s Biopharmaceutical Pipeline Table 4-7 (continued) GlaxoSmithKline’s Biopharmaceutical Pipeline Table 4-8 Merck KGaA’s Biopharmaceutical Pipeline Table 4-9 Novartis’ Biopharmaceutical Pipeline Table 4-10 Novo Nordisk’s Biopharmaceutical Pipeline Table 4-11 Pfizer’s Biopharmaceutical Pipeline Table 4-11 (continued) Pfizer’s Biopharmaceutical Pipeline Table 4-12 Roche’s Biopharmaceutical Pipeline (including Genentech) Table 4-12 (continued) Roche’s Biopharmaceutical Pipeline (including Genentech) Table 4-12 (continued) Roche’s Biopharmaceutical Pipeline (including Genentech)
  • 8. CHAPTER FIVE: ISSUES AND TRENDS Table 5-1 International Population Trend Age 65+ International Population Trend Age 65+ Table 5-2 United States Population Trend Age 65+ United States Population Trend Age 65+ Table 5-3 Recent Biopharmaceutical Business Mergers and Acquisitions Table 5-4 Pharmaceutical/Biopharmaceutical R&D Statistics Table 5-5 Total Industry R&D Spending 2004-2010 Table 5-6 Pharmaceutical and Biopharmaceutical Cancer Drugs in Development 2011 CHAPTER SIX: MARKET SUMMARY Table 6-1 Global Biopharmaceutical Treatments (non-vaccine)Market, 2008-2015 Compound Annual Growth Rate Figure 6-1 Global Biopharmaceutical Treatments (non-vaccine)Market, 2008- 2015 Table 6-2 Global Biopharmaceutical Treatments (non-vaccine)Market by Product Category Figure 6-2 Global Biopharmaceutical Treatments (non-vaccine)Market by Product Category Table 6-3 Leading Biotech Therapies by 2010 Revenues Table 6-4 Global Biopharmaceutical Treatments (non-vaccine)Market Forecast by Product Category, 2010 and 2015—based on late stage development Figure 6-3 Global Biopharmaceutical Treatments (non-vaccine)Market Forecast by Product Category, 2010 and 2015—based on late stage development Table 6-5 Biopharmaceutical Treatments (non-vaccine)Sales by Region, 2008- 2010 and Forecast through 2015 Figure 6-4 Biopharmaceutical Treatments (non-vaccine)Sales by Region, 2008- 2010 and Forecast through 2015 Figure 6-5 Estimated Biopharmaceutical Treatments (non-vaccine)Sales by Broad Region, 2010 Table 6-6 Competitor Market Shares and Revenues for Biopharmaceutical Therapies, 2010 Figure 6-6 Biopharmaceutical Sales by Company, 2008-2010 Figure 6-7 Competitor Market Shares for Biopharmaceutical Therapies, 2010 Table 6-7 Top Three Competitors for Autoimmune Biopharmaceutical Treatments, 2010 Figure 6-8 Competitor Market Shares: Autoimmune Biopharmaceutical Therapies, 2010 Table 6-8 Top Three Competitors for Cancer Biopharmaceutical Treatments, 2010 Figure 6-9 Competitor Market Shares: Cancer Biopharmaceutical Treatments, 2010 Table 6-9 Top Three Competitors for Cardiovascular/Blood Disorder Biopharmaceutical Treatments, 2010 Figure 6-10 Competitor Market Shares: Cardiovascular/Blood Disorder Biopharmaceutical Treatments, 2010
  • 9. Table 6-10 Top Three Competitors for Hormone Biopharmaceutical Treatments, 2010 Figure 6-11 Competitor Market Shares: Hormone Biopharmaceutical Treatments, 2010Available immediately for Online Download athttp://www.marketresearch.com/product/display.asp?productid=6329805US: 800.298.5699UK +44.207.256.3920Intl: +1.240.747.3093Fax: 240.747.3004

×